Although PARP inhibitors were found to be selectively active in a subset of tumors harboring BRCA1 or BRCA2 mutations due to the synthetic lethality of PARP inhibition and this particular HRD, it also has a role in BRCA wild type cancers [65,66]. Here, BRCA2 is linked to cancer.